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Background: Haematological disorders, in particular sickle cell disease (SCD) and thalassaemia, are
relatively common in Oman. We report our experience of splenectomy for haematological disorders and
review the literature on splenectomy role in their management.
Objectives: To review our experience in the management of 150 patients with haematological disorders
undergoing splenectomy with emphasis on indications and outcome. To compare our experience with
those reported from outside this region.
Methods: The records of 150 patients who underwent splenectomy over a thirteen year period were
reviewed retrospectively, analyzing the age and sex of the patients, indication for splenectomy, operative
procedures, complications, peri-operative management and outcome.
Results: Of the 150 patients, 96 (64%) had SCD and 34 (22.6%) had b-thalassaemia; the rest comprised
patients with refractory idiopathic thrombocytopenic purpura (ITP) n¼ 12, hereditary spherocytosis (HS)
n¼ 6, and auto-immune haemolytic anaemia (AHA) n¼ 2. In SCD patients, the main indications for
splenectomy were recurrent splenic sequestration (60.4%) and hypersplenism (36.4%), whereas in tha-
lassaemic patients it was increased requirement of packed red blood cells (PRBC) transfusion (mean
310 ml, range 242–372 of PRBC/kg/year). All patients received prophylactic antibiotics and vaccination
against pneumococcal infection and when the vaccine was available for Haemophilus inﬂuenzae. PRBC
and platelet concentrates as well as intravenous ﬂuids were infused preoperatively as per protocol.
Concomitant procedures at laparotomy included liver biopsy (14.6%) and cholecystectomy (8.6%). The
postoperative morbidity was low (8.6%) and there was no mortality. All patients were maintained on long
term penicillin and proguanil, and the mean follow-up was 4.6 years. In SCD patients splenectomy
eliminated the risks of life threatening acute splenic sequestration and improved signiﬁcantly the blood
counts of the hypersplenic cases, while in thalassaemic patients it reduced signiﬁcantly the mean
transfusion requirement by 100 ml PRBC/kg/year (p< 0.0001). Of the patients with refractory ITP, two
thirds had a good response to splenectomy (p< 0.0001). All HS and AHA patients beneﬁted from
splenectomy.
Conclusion: The predominant indications for splenectomy were recurrent acute splenic sequestration and
hypersplenism in SCD patients, and increased transfusion demand in the thalassaemics. Overall, sple-
nectomy proved beneﬁcial in eliminating the risk of splenic sequestration in SCD patients, in improving
the blood counts in SCD with hypersplenism and in reducing transfusion requirement in thalassaemic
patients, while in ITP group two thirds of the patients beneﬁted.
 2009 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved., Sultan Qaboos University
Fax: þ968 24413851.
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Splenectomy is widely performed for a variety of haematological
disorders in which the spleen is felt to exert a destructive effect on
the blood cells, thereby causing thrombocytopenia, anaemia,
leukopenia or a combination of these effects.1,2 Haematologicald. All rights reserved.
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common in Oman and parts of the Middle East.3–7 A signiﬁcant
number of patients with these disorders are often referred for
splenectomy because of splenic dysfunction. The role of splenec-
tomy in some haematological disorders is well established but the
pattern of diseases reported from outside the region appears
different from our experience.1,2,8,9
We report here a retrospective study of our experience with
open splenectomy for haematological disorders over a thirteen year
period with the aim of determining the indications, complications
and the outcome of splenectomy.
2. Patients and methods
The records of 150 patients who underwent open splenectomy
for haematological disorders at our institution from January 1993 to
December 2005 were reviewed retrospectively. Patients who
underwent laparoscopic splenectomy since 2005were not included
in this study. Variables analyzed included the age and sex of the
patient, the haematological disorder, the indication for splenec-
tomy, preoperative preparation, peri-operative transfusions, oper-
ative procedures, peri-operative complications and outcome of
splenectomy. The diagnosis of a haematological disorder was
established on the basis of the clinical features of the patients and
the results of conventional laboratory methods including haemo-
globin electrophoresis. The criteria for the diagnosis of hyper-
splenism included splenomegaly with accompanying anaemia,
leukopaenia, thrombocytopenia or any combination of these with
hypercellular bone marrow. In patients with SCD, acute splenic
sequestration was divided into major and minor attacks. The minor
attacks were characterized by moderate increase in splenic size
associated with a fall in haemoglobin level of 2–3 g/dl whilst
a major attack was characterized by a greater drop in haemoglobin
level by more than 4 g/dl, below the basal haemoglobin level of the
patient.
Our management protocol for elective splenectomy required
that all patients be given polyvalent pneumococcal vaccine (0.5 ml
of PMY – Immune 23, Lederle), and Haemophilus inﬂuenzae vaccine,
at least one month before splenectomy. The patients were also
routinely screened for gallstones by ultrasound. PRBC and platelet
concentrates as well as intravenous ﬂuids were infused preopera-
tively when necessary. With SCD patients, our initial practice was
preoperative exchange transfusion to lower haemoglobin S levels to
around 30% but this practice was changed in 1996 to a policy of top-
up transfusions only, to raise the haemoglobin level to around 10 g/dl
preoperatively. All patients were covered with intravenous cefur-
oxime 750 mg IV BD for 5 days postoperatively with the ﬁrst dose
given at induction; they were then switched to oral penicillin
postoperatively. On discharge, the patients were covered prophy-
lactically with oral penicillin and an antimalarial drug, proguanil.
Patients with thalassaemia who required transfusion every month
also received desferoximine infusion ﬁve days aweek. The outcome
of splenectomy was assessed by its ability to eliminate the risk of
acute splenic sequestration and improve the blood counts; reduceTable 1
Characteristics of 150 patients with haematological disorders who underwent splenecto
Haematological disorder n (%) Age (years)
Median
Sickle cell disease 96 (64) 6.25 SD 1.18
b-Thalassaemia 34 (22.6) 9. 8 SD 4.16
ITP 12 (8) 19.4 SD 15.4
Hereditary spherocytosis 6 (4) 29.5 SD 24.11
Auto-immune haemolytic anaemia 2 (1.4) 3.5 SD 0.5the transfusion requirements; improve the platelet counts and
improve the Hb levels in SCD, thalassaemia, ITP, and hereditary
spherocytosis patients respectively.
The long-term follow-up of the majority of patients was carried
out by our paediatric and haematology units; whilst a few were
followed up by the referring institutions.
The preoperative value was taken as the mean of blood counts
recorded before any blood transfusion was given, while the post-
operative value was the mean of multiple estimations performed
during out-patient follow-up. Postoperatively blood counts were
checked once every twomonths for a minimum of one year follow-
up. For thalassaemic patients the average PRBC transfusion
requirement was calculated as ml/kg/year in the preoperative and
postoperative periods and the difference noted. In patients with ITP
the response to splenectomy was determined by comparing the
mean preoperative platelet count before surgery with that obtained
postoperatively.
2.1. Statistical methodology
Student’s ‘t’ test was used to assess the signiﬁcance of differ-
ences between preoperative and postoperative measurements for
different parameters. In case of non-parametric variables, Mann–
Whitney U test was used instead of t test and a p value of 0.05 or
less was considered as statistically signiﬁcant. Data were processed
using SAS version 8.2 (Cary, NC, USA).
3. Results
The characteristics of the 150 patients who underwent sple-
nectomy and the indications for the same are summarized in
Tables 1 and 2 respectively. The mean age in the study group was
variable. The youngest patients were those with auto-immune
haemolytic anaemia (median age 3.5 0.5), followed by SCD
(6.251.78) and thalassaemia (9.8 4.16). However patients
undergoing splenectomy for ITP and hereditary spherocytosis were
older, with a median age of 19.415.4 and 29.5 24.11 respec-
tively. While in SCD and thalassaemia the males were affected
nearly twice as often as female patients, among patients with ITP
and hereditary spherocytosis there was a female preponderance.
The mean preoperative Hb levels in SCD and thalassaemia patients
were 6.15 and 6.55 g/dl respectively. The mean Hb F level in
patients with SCD was 21.2% (10.1–38.6%). The predominant indi-
cation for splenectomy in SCD was splenic sequestration (60.4%)
and hypersplenism (36.4%). In patients with SCD splenectomy was
considered after two minor attacks or one major attack of seques-
tration crisis. Ten of our patients required splenectomy for major
sequestration crisis and the Hb at the time of admission in these
patients ranged from 1.7 to 4 g%. (Mean 2.6 g%). In patients with
b-thalassaemia the main indication for splenectomy was PRBC
transfusion requirement exceeding a mean of 310 ml/kg/year
(range 242–372 ml/kg/year). All 12 patients with ITP had received
immunoglobulin and steroid therapy over an average period of six
months and were only considered for splenectomy when theymy.
Sex M/F Weight of spleen (g)
Range Mean (Range)
(2–40) 60/36 577 (90–1243)
(4–19) 23/11 524 (147–1254)
(3–45) 5/7 263 (95–910)
(11–75) 1/5 546 (330–837)
(3–4) 0/2 157 (130–185)
Table 2
Indications for splenectomy in 150 patients with haematological disorders.
Haematological disorder Indications for splenectomy (n) %
Sickle cell disease Recurrent splenic sequestration 58a (60.4)
Hypersplenism 35 (36.4)
Splenic abscess 3 (3.2.)
b-Thalassaemia Increased blood transfusion
requirement (>250 ml/kg/year)
34
ITP Increased platelet infusion
requirement/steroid resistance
12
Hereditary spherocytosis Anaemia/generalized weakness 6
Auto-immune haemolytic
anaemia
Anaemia/haemolysis 2
a 8 of these patients had hypersplenism as well.
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steroid therapy. The six patients with HS were offered splenectomy
because of severe anaemia causing generalized weakness and, in
addition, four of them had symptomatic gallstones. The two
patients with auto-immune haemolytic anaemia underwent sple-
nectomy for persistent symptomatic anaemia.
The average serum ferritin level in the thalassaemic patients
was 2088 ng/ml. Preoperative transfusion was required in the
majority of patients. In the SCD group the initial thirty-ﬁve patients
had preoperative exchange transfusion but the next lot of sixty-one
patients had top-up transfusions only, to raise the preoperative
haemoglobin level to 10 g/dl with equally satisfactory results. Of
the 150 patients in the series, 147 received pneumococcal vacci-
nation 4–8 weeks prior to undergoing splenectomy. The remaining
three were SCD patients who underwent emergency splenectomy
for splenic abscess were vaccinated postoperatively.
Dense adhesions between the spleen and diaphragm requiring
sharp dissection were encountered at laparotomy in 35 (36.5%) of
the SCD patients but were not seen in the other haematological
conditions. Two of these patients sustained small tears in the dia-
phragm during adhesiolysis; both were promptly repaired. Thirty
(20%) of the SCD patients in the series had accessory splenunculi,
with an average of three splenunculi per patient. Concomitant
procedures carried out included cholecystectomy for gallstones in
13 (9.8%) patients among whom, three patients were symptomatic
and the remaining were asymptomatic and gallstones were
detected during routine preoperative abdominal ultrasound
examination. Liver biopsy was carried out in 22 (14.6%) patients,
mostly in thalassaemics, for gross hepatomegaly and/or persis-
tently abnormal levels of liver enzymes. In sixteen thalassaemics,
the liver biopsy revealed features of secondary haemosiderosis.
There were six instances of early postoperative complications.
Two SCD patients developed acute chest syndrome postoperatively
including one following an emergency splenectomy for a large
splenic abscess. Another SCD patient developed postoperative feverFig. 1. (A) Improvement in mean haemoglobin and WBC counts pre- and postsplenthat persisted for over a week and for which no cause was found.
One thalassaemic patient developed cavernous sinus thrombosis
and was discovered to have protein C deﬁciency; she recovered
fully with conservative therapy. One ITP patient who remained
refractory after splenectomy developed an intracranial bleed,
which was managed conservatively with platelet infusions and
steroids. There were no surgical site infections but one patient with
concomitant hypoalbuminaemia had a partial wound dehiscence.
There was no mortality in this series. One SCD patient presented
with adhesive intestinal obstruction one year after splenectomy
and eventually required laparotomy.
The follow-up period ranged from two years to eight years with
a mean of 6.6 years. The impact of splenectomy on the blood counts
of the study patients is shown in Fig. 1 and the long term outcome
on the various disorders is summarized in Table 3. In patients with
SCD there was a signiﬁcant improvement in the blood counts
postsplenectomy with a median increase of Hb by 3.4 g%, haema-
tocrit by 10.7%, WBC by 4.54109/L and platelets by 235109/L.
Similar improvements were also noted in thalassaemic patients
with hypersplenism. In patients with ITP a good response was seen
in 8 of the 12 patients (66%)with rise in platelet count by 244109/L
(Fig. 1). All patients with hereditary spherocytosis had relief of their
symptoms of tiredness as a consequence of improvement of their
Hb level by 3.35 g%. While splenectomy eliminated life threatening
complication of splenic sequestration, thirty seven of the SCD
patients were re-admitted at various times during the follow-up
period with disease-related complications namely, vaso-occlusive
crisis {n¼ 20}, acute chest syndrome {n¼ 6}, chest infections
{n¼ 3}, osteonecrosis {n¼ 5}, and osteomyelitis {n¼ 4}. Two of 25
thalassaemic patients followed up at our institution developed
diabetes and were on insulin therapy. The four ITP patients who
responded poorly to splenectomy continued to require steroids.
Two of these patients who were screened for accessory splenunculi
by radiolabelled scan were negative. The other two refused any
further investigations. The patients with HS and AHA maintained
their good response.
4. Discussion
The options in the management of patients with splenic
sequestration crisis include splenectomy, or careful observation
with chronic transfusion programmes and prompt therapy of
recurrent events.14–16 With conservative management the risk of
recurrent splenic sequestration is approximately 50% and the
mortality rate from the recurrent events is signiﬁcant with rates as
high as 20%.15,16 Chronic transfusionmay restore or improve splenic
function but it is unclear how to monitor its effect or when to stop
such a programme with all the associated risks of transfusion.15,17
Splenectomy prevents further acute splenic sequestration without
the risks of chronic transfusion. It has also been reported to reduceectomy. (B) Improvement in mean platelet counts pre- and post splenectomy.
Table 3
Outcome of splenectomy.
Haematological disorder Outcome
Sickle cell disease (n¼ 96)  Risk of acute splenic sequestration
eliminated
 In hypersplenic patients Hb [
by >3.00 g/dl along with [ in WBC and
platelet count (p< 0.0001)
b-Thalassaemia (n¼ 34) Reduction in transfusion requirement
by 100 ml PRBC/kg/year (p< 0.0001)
ITP (n¼ 12)  Good response
(platelet count> 100 109) – 8 patients
 Poor response
(platelet count< 50 109/L) – 4 patients
Hereditary spherocytosis (n¼ 6)  Good response in all patients
Post splenectomy Hb [ by >3.00 g/dl
(p< 0.0001)
AHA (n¼ 2)  Good response in both patients
 Hb [ by 3.8 g/dl
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and by 45% for 6–12 months following splenectomy in children.18
Generally, splenectomy is seriously considered after two minor
episodes or onemajor episode of sequestration, as in our series; but
it may be carried out even after a single minor attack if social
circumstances are adverse such as inability of parents or guardians
to understand the seriousness of the problem, and difﬁculty in
accessing transport to the hospital.5,6,10 In one of the reports sple-
nectomy was indicated in 12.4% of cases after the ﬁrst minor
episode and in 60.5% of cases in the second episode.12 The risks of
chronic transfusion also apply in the management of hyper-
splenism. Most of our SCD patients with hypersplenism of more
than six months duration were considered for splenectomy, with
resultant signiﬁcant improvement in the blood counts. While
splenectomy improves the haematological proﬁle and eliminates
splenic sequestration crises, there is however, lack of evidence from
clinical trials that it improves survival and decreases morbidity.17
In patients with thalassaemia major, an adequate transfusion
regimen is needed to suppress endogenous erythropoiesis and to
prevent bone malformation and cardiomegaly.19 Optimal clinical
management may delay or prevent hypersplenism. Many of our
patients had been poorly managed in other centers in the past and
had developed massive splenomegaly and hypersplenism with
consequent increase in transfusion requirements. As a conse-
quence, the average presplenectomy serum ferritin level in our
patients was 2088 ng/ml and the majority of the patients who had
liver biopsy showed secondary haemosiderosis. Most of these
patients, like ours, needed iron chelation therapy to lower the iron
overload.20 Splenectomy signiﬁcantly reduced the transfusion
requirements in our patients below 100 ml/kg/year and, thus the
degree of further iron overloading also was relatively diminished.
The indications for splenectomy in our patients appear different
from that of other regions. While the common indications for
splenectomy in the western hemisphere are ITP, hereditary spher-
ocytosis, lymphoma and myeloproliferative disorders,8,9 in our
series SCD and thalassaemia were the predominant indications, an
experience similar to those in other middle eastern countries.4–7
Among the SCD patients, the main indication for splenectomy
irrespective of the age was acute splenic sequestration. This is in
contrast to the Latin American, North American and Caribbean
experience in which acute splenic sequestration was the predom-
inant indication for splenectomy in SCD patients under 5 years10–13
while hypersplenism predominated in those over 5 years.10,11 Acute
splenic sequestration crisis is usually seen in children younger than
2 years but of interest was the ﬁnding that our patients were older
(mean 6.25 years) compared to reports from other part of the
world.10–13 While the exact reason for this is unclear onecontributing factor is the persistence of splenomegaly in our
patients into older age group. This is partly attributed to high
incidence of alpha thalassaemia seen in our patients.
The overall response to splenectomy in ITP varies from 55 to 86%
in various series.21–25 It has been shown, using radionuclide platelet
kinetic study, that younger ITP patients primarily have splenic
sequestration, whereas, hepatic sequestration is more likely to
occur in older patients.19,22 A high success rate of 93% has been
achieved for splenectomy in patients with purely splenic seques-
tration as compared with 26% for mixed or hepatic sequestration,
prompting some authors to advocate the performance of platelet
kinetic studies in all patients with ITP before being considered for
splenectomy.25 Such studies were not performed in our limited
series due to the lack of relevant facilities locally. However, the
uncertainty associated with relapse in splenectomized patients,
evolving new understanding of the pathophysiology, and the
emergence of new agents associated with durable remission with
intact spleens, the therapeutic approach to management of ITP is
rapidly evolving.21,23
The incidence of HS was low in our series; 4.9% compared to 8–
12% in some series.5,8 This may reﬂect a genuinely low prevalence
of the disorder in the community or may simply be a relative ﬁgure
in view of the high incidence of haemoglobinopathy. Complications
of pigment stones occur frequently in adult patients with HS and
were seen in four of our six patients; inwhom splenectomy may be
combined with cholecystectomy, as we did in these cases. The good
response to splenectomy achieved in our patients is consistent with
the results of other reported series.5,8
Splenunculi were noted in 20% of our patients, a ﬁgure similar to
other reports.8,26 While the clinical signiﬁcance of accessory
spleens in patients with recurrence of ITP in the postsplenectomy
phase is well known27,28 its relevance in patients with thalassaemia
and SCD is not clear. In patients with SCD repeated vaso-occlusive
episodes may ﬁnally lead to their atrophy. A thorough intra-
operative search for accessory spleen at the common locations is
generally the most efﬁcient way to prevent the failure of splenec-
tomy.28 Some authorities have even recommended the intra-
operative detection of accessory spleen using radiolabelled
platelets with a sterile probe counter.28
Laparoscopic splenectomy has been described as a safe and
feasible alternative to open splenectomy both in children and
adults.13,18,28–30 In patients with ITP, laparoscopic splenectomy is
technically easier because of the smaller spleens in older patients.
However, in SCD patients it poses special problems due to the
excessively large spleens in small children, compounded by
multiple adhesions frequently seen in these patients due to
previous sequestration/infarctions, making them a relative
contraindication for the laparoscopic approach. Nevertheless
successful laparoscopic splenectomy has been reported in children,
with a distinctive advantage of shorter hospital stay, lower inci-
dence of postoperative acute chest syndrome (ACS) and lower
wound related complications.13,18,29,30 The decrease in the inci-
dence of postoperative ACS in laparoscopic splenectomy (5.2%)
compared to open procedure (33.3%) has been attributed to several
factors including reduced manipulation and breaching of fat during
laparoscopy, preventing fat embolism and thrombosis in locally
damaged tissue vessels, reduced risk of inoculation of organism
into the wound site and decreased incidence of postoperative
hypoventilation due to reduced postoperative pain.30 In our study
the mean spleen weight in SCD and thalassaemic patients was 577
and 524 g, as compared with the mean age of 6.25 and 9.8 years
respectively, indicating that these patients had relatively large
spleens in younger children. However in ITP patients with a mean
age of 29.5 years, the mean weight of the spleen was almost half at
263 g of that of SCD and thalassaemia patients [Table 1]. In our
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since 2005, for ITP and smaller sized spleens in SCD patients, these
cases have not been included in the analysis of this group of
patients who have undergone open splenectomy.
The complications associated with splenectomy for haemato-
logical disorders reported in old publications ranged from 13% to
49%, with mortality rates of 6% to 27%.2,8,31 With improvements in
surgical and anaesthetic techniques and better understanding of
the pathophysiology of various haematological disorders, these
ﬁgures have improved signiﬁcantly as noted in recent publications
and in our own experience.12,13,18,29,30 Our initial practice of
preoperative exchange transfusion in sickle cell disease patients to
lower HBS to 30% was replaced by top-up transfusion to raise the
preop Hb to 10 g% with good result; the good outcome of this
practice has also been reported by others.14The risk of over-
whelming post splenectomy infection is well known and although
prophylactic antibiotics and pneumococcal immunization should
decrease the incidence of overwhelming sepsis, some have advo-
cated alternatives to total splenectomy.32–34 In a major collective
review of over 2795 patients to assess postsplenectomy infection,
the incidence was found to be 4.24% with mortality rate of 2.52% in
children under 16 years of age with the corresponding ﬁgures for
adults being 0.9% and 0.8%.35 There are no reliable data relating to
efﬁcacy of chemoprophylaxis in asplenic patients though guide-
lines have recommended life-long antibiotics.36,37 Concern over
increasing resistance of especially pneumococci to the commonly
used prophylactic agents together with patients compliance difﬁ-
culties have inﬂuenced others to advise that the antibiotics should
be kept at home to self prescribe at the ﬁrst sign of possible
infection.37 Recently the use of heptavalent pnuemococcal protein
conjugate vaccine has been recommended particularly in children
as it is believed to confer better protective response compared to
pnuemococcal polysaccharide polyvalent vaccine.39 The impor-
tance of different preventive strategies such as immunization,
revaccination, antibiotic prophylaxis and the need to carry stand-by
antibiotics have to be discussed with the patients.37 The patients
are also encouraged to carry a card documenting immunization and
prophylactic antibiotics in use and a plan for emergencies.37 We
believe the use of peri-operative antibiotics, pneumococceal
vaccine and H. inﬂuenzae vaccine, along with long term penicillin
prophylaxis, have played a signiﬁcant role in the reduction of
infections in our patients. While children under 5 years are
particularly prone to infection by capsulated and other organ-
isms,31,38–40 it has been our practice to cover all our patients with
long term penicillin prophylaxis.
In conclusion, the predominant haematological disorders
requiring splenectomy in our series were SCD and thalassaemia
compared to ITP, hereditary spherocytosis and lymphoma in the
western countries. The major indication for splenectomy in SCD
was splenic sequestration which was seen in slightly older chil-
dren when compared to others experience. Splenectomy has
proved generally beneﬁcial in the management of speciﬁc splenic
complications associated with SCD, b-thalassaemia and other
haematological disorders in our setting. In patients with SCD it
eliminated the risk of life threatening complications of acute
splenic sequestration and improved the blood counts signiﬁ-
cantly while in thalassaemic patients it reduced the transfusion
requirement by 100 ml/kg/year and consequently reduced the
risk of complications associated with iron overload. All patients
with hereditary spherocytosis had signiﬁcant improvement in
their symptoms and in two thirds of ITP patients the outcome
was good.
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